CL2011000047A1 - Anticuerpo antagonista que se une específicamente al receptor 4 del factor de crecimiento fibroblástico (fgf-r4); uso de dicho anticuerpo porque sirve para inhibir la angiogénesis patológica y tratar cáncer hepático y pancreático; composición que lo comprende; linea celular; polinucleótido y vector que comprenden dicho anticuerpo. - Google Patents

Anticuerpo antagonista que se une específicamente al receptor 4 del factor de crecimiento fibroblástico (fgf-r4); uso de dicho anticuerpo porque sirve para inhibir la angiogénesis patológica y tratar cáncer hepático y pancreático; composición que lo comprende; linea celular; polinucleótido y vector que comprenden dicho anticuerpo.

Info

Publication number
CL2011000047A1
CL2011000047A1 CL2011000047A CL2011000047A CL2011000047A1 CL 2011000047 A1 CL2011000047 A1 CL 2011000047A1 CL 2011000047 A CL2011000047 A CL 2011000047A CL 2011000047 A CL2011000047 A CL 2011000047A CL 2011000047 A1 CL2011000047 A1 CL 2011000047A1
Authority
CL
Chile
Prior art keywords
antibody
fgf
polynucleotide
vector
serves
Prior art date
Application number
CL2011000047A
Other languages
English (en)
Inventor
Nicolas Baurin
Pierre-Francois Berne
Fracis Blanche
Bonofrancoise
Beatrice Cameron
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40626849&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2011000047(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of CL2011000047A1 publication Critical patent/CL2011000047A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Anticuerpo antagonista que se une específicamente a fgf-r4; uso de dicho anticuerpo porque sirve para inhibir la angiogénesis; composición que lo comprende; línea celular; polinucleótido y vector que comprenden dicho anticuerpo.
CL2011000047A 2008-07-08 2011-01-07 Anticuerpo antagonista que se une específicamente al receptor 4 del factor de crecimiento fibroblástico (fgf-r4); uso de dicho anticuerpo porque sirve para inhibir la angiogénesis patológica y tratar cáncer hepático y pancreático; composición que lo comprende; linea celular; polinucleótido y vector que comprenden dicho anticuerpo. CL2011000047A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0803888A FR2933702A1 (fr) 2008-07-08 2008-07-08 Antagonistes specifiques du recepteur fgf-r4

Publications (1)

Publication Number Publication Date
CL2011000047A1 true CL2011000047A1 (es) 2011-07-08

Family

ID=40626849

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2011000047A CL2011000047A1 (es) 2008-07-08 2011-01-07 Anticuerpo antagonista que se une específicamente al receptor 4 del factor de crecimiento fibroblástico (fgf-r4); uso de dicho anticuerpo porque sirve para inhibir la angiogénesis patológica y tratar cáncer hepático y pancreático; composición que lo comprende; linea celular; polinucleótido y vector que comprenden dicho anticuerpo.

Country Status (38)

Country Link
US (1) US20110150903A1 (es)
EP (1) EP2315781B1 (es)
JP (2) JP5726731B2 (es)
KR (1) KR20110028536A (es)
CN (2) CN103784954A (es)
AR (1) AR072699A1 (es)
AU (1) AU2009267834B2 (es)
BR (1) BRPI0915660A2 (es)
CA (1) CA2730300A1 (es)
CL (1) CL2011000047A1 (es)
CO (1) CO6440535A2 (es)
CR (1) CR11868A (es)
CY (1) CY1116847T1 (es)
DK (1) DK2315781T3 (es)
DO (1) DOP2011000005A (es)
EA (2) EA201401107A1 (es)
EC (1) ECSP11010748A (es)
ES (1) ES2544761T3 (es)
FR (1) FR2933702A1 (es)
HK (1) HK1159133A1 (es)
HN (1) HN2011000074A (es)
HR (1) HRP20150836T1 (es)
HU (1) HUE027221T2 (es)
IL (1) IL210516A0 (es)
MA (1) MA32547B1 (es)
MX (1) MX2011000328A (es)
NI (1) NI201100012A (es)
NZ (2) NZ602905A (es)
PE (1) PE20110313A1 (es)
PL (1) PL2315781T3 (es)
PT (1) PT2315781E (es)
SG (1) SG10201403751XA (es)
SI (1) SI2315781T1 (es)
TW (1) TW201006492A (es)
UA (1) UA107782C2 (es)
UY (1) UY31970A (es)
WO (1) WO2010004204A2 (es)
ZA (1) ZA201100209B (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107090045A (zh) * 2010-05-03 2017-08-25 霍夫曼-拉罗奇有限公司 用于肿瘤诊断和治疗的组合物和方法
US8906649B2 (en) 2010-09-27 2014-12-09 Janssen Biotech, Inc. Antibodies binding human collagen II
EP2621950A4 (en) * 2010-09-27 2015-09-02 Janssen Biotech Inc ANTIBODIES FOR BINDING HUMAN COLLAGEN II
KR20140021589A (ko) * 2011-04-07 2014-02-20 제넨테크, 인크. 항-fgfr4 항체 및 사용 방법
JO3283B1 (ar) 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
CN102219860B (zh) * 2011-05-20 2012-09-12 烟台荣昌生物工程有限公司 FGFR-Fc融合蛋白及其用途
EP2723391B1 (en) * 2011-06-24 2018-06-13 University of Miami Fibroblast growth factor receptor inhibition for the treatment of disease
US8951966B2 (en) 2011-07-01 2015-02-10 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides, and uses and methods thereof for treatment of metabolic disorders and diseases
US9290557B2 (en) 2012-11-28 2016-03-22 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides
ES2828505T3 (es) 2012-11-28 2021-05-26 Ngm Biopharmaceuticals Inc Composiciones y métodos para el tratamiento de trastornos y enfermedades metabólicos
US9273107B2 (en) 2012-12-27 2016-03-01 Ngm Biopharmaceuticals, Inc. Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
IL292303A (en) 2012-12-27 2022-06-01 Ngm Biopharmaceuticals Inc Methods of regulating bile acid homeostasis and treatment of bile acid disorders and diseases
WO2014105849A1 (en) * 2012-12-28 2014-07-03 Xoma (Us) Llc Antibodies specific for fgfr4 and methods of use
WO2014165287A1 (en) * 2013-03-12 2014-10-09 The Translational Genomics Research Institute Hybridoma clones and monoclonal antibodies to fibroblast growth factor 4
US9957313B2 (en) 2013-03-15 2018-05-01 Remegen, Ltd. FGFR-FC fusion proteins and the use thereof
AU2014338549B2 (en) 2013-10-25 2017-05-25 Novartis Ag Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors
EP3062881B1 (en) 2013-10-28 2019-10-02 NGM Biopharmaceuticals, Inc. Cancer models and associated methods
WO2015107171A1 (en) * 2014-01-17 2015-07-23 Sanofi Methods of identifying patients suffering from liver cancer who will most likely benefit from a treatment with an antagonist anti-fgfr4 antibody
JP6837840B2 (ja) 2014-01-24 2021-03-10 エヌジーエム バイオファーマシューティカルス，インコーポレーテッド 結合タンパク質及びその使用方法
US10398758B2 (en) 2014-05-28 2019-09-03 Ngm Biopharmaceuticals, Inc. Compositions comprising variants of FGF19 polypeptides and uses thereof for the treatment of hyperglycemic conditions
EP3155005A4 (en) 2014-06-16 2018-07-11 NGM Biopharmaceuticals, Inc. Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
TR201909951T4 (tr) 2014-07-18 2019-07-22 Sanofi Sa Kanser olduğundan şüphelenilen bir hastanın aflibersept ile tedavisinin sonucunun öngörülmesine yönelik yöntem.
CN104177492B (zh) * 2014-07-21 2017-02-22 暨南大学 FGFR2c胞外段类似物及其编码基因与应用
PL3180356T3 (pl) * 2014-08-11 2020-04-30 Daiichi Sankyo Europe Gmbh Ludzkie przeciwciało anty-fgfr4
WO2016054483A1 (en) 2014-10-03 2016-04-07 Novartis Ag Use of ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors
US10517929B2 (en) 2014-10-23 2019-12-31 Ngm Biopharmaceuticals, Inc. Pharmaceutical compositions comprising FGF19 variants
WO2016073855A1 (en) 2014-11-07 2016-05-12 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders
WO2016151499A1 (en) 2015-03-25 2016-09-29 Novartis Ag Formylated n-heterocyclic derivatives as fgfr4 inhibitors
EP3095465A1 (en) 2015-05-19 2016-11-23 U3 Pharma GmbH Combination of fgfr4-inhibitor and bile acid sequestrant
US10800843B2 (en) 2015-07-29 2020-10-13 Ngm Biopharmaceuticals, Inc. Beta klotho-binding proteins
JP6728352B2 (ja) 2015-11-09 2020-07-22 エヌジーエム バイオファーマシューティカルス，インコーポレーテッド 胆汁酸に関係した障害の治療方法
WO2017100642A1 (en) 2015-12-11 2017-06-15 Regeneron Pharmaceuticals, Inc. Methods for reducing or preventing growth of tumors resistant to egfr and/or erbb3 blockade
WO2017137503A1 (en) 2016-02-10 2017-08-17 Daiichi Sankyo Europe Gmbh Combination of human anti-fgfr4 antibody and sorafenib
TW202409084A (zh) 2016-03-04 2024-03-01 美商Ｊｎ生物科學有限責任公司 針對tigit之抗體
US11370841B2 (en) 2016-08-26 2022-06-28 Ngm Biopharmaceuticals, Inc. Methods of treating fibroblast growth factor 19-mediated cancers and tumors
WO2018055503A1 (en) 2016-09-20 2018-03-29 Novartis Ag Combination comprising a pd-1 antagonist and an fgfr4 inhibitor
CA3042475C (en) 2016-11-02 2024-01-16 Novartis Ag. Combinations of fgfr4 inhibitors and bile acid sequestrants
IL266769B2 (en) * 2016-11-22 2024-04-01 Merck Patent Gmbh FGFR1-specific monoclonal antibodies and their preparation
EP3444275A1 (en) * 2017-08-16 2019-02-20 Exiris S.r.l. Monoclonal antibody anti-fgfr4
CN109725159B (zh) * 2018-12-28 2021-10-08 江苏众红生物工程创药研究院有限公司 人β2-微球蛋白的定量检测试纸卡与临床应用
CN115551538A (zh) * 2020-01-21 2022-12-30 拓维创新生物科技(香港)有限公司 干扰IL-1β受体信号转导的药剂
PE20231078A1 (es) 2020-06-02 2023-07-17 Arcus Biosciences Inc Anticuerpos anti-tigit
WO2022098662A2 (en) * 2020-11-03 2022-05-12 Twist Bioscience Corporation Methods and compositions relating to chemokine receptor variants
CN118108840A (zh) * 2022-11-29 2024-05-31 中国科学院深圳先进技术研究院 抗fgfr4单克隆抗体、靶向fgfr4的嵌合抗原受体t细胞及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) * 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) * 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
ES2136092T3 (es) * 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
PT1242438E (pt) * 1999-12-29 2007-02-28 Immunogen Inc Agentes citotóxicos compreendendo dixorrubicinas e daunorrubicinas modificadas e seu uso terapêutico
ATE506077T1 (de) * 2003-10-16 2011-05-15 Imclone Llc Fibroblasten-wachstumsfaktor-1-hemmer und behandlungsverfahren dafür
WO2007136893A2 (en) * 2006-02-10 2007-11-29 Genentech, Inc. Anti-fgf19 antibodies and methods using same
JP5570218B2 (ja) * 2006-11-03 2014-08-13 ユースリー ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｆｇｆｒ４抗体
EP1918376A1 (en) * 2006-11-03 2008-05-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. FGFR4 promotes cancer cell resistance in response to chemotherapeutic drugs
RU2009136669A (ru) * 2007-03-09 2011-04-20 Новартис АГ (CH) Лечение меланомы

Also Published As

Publication number Publication date
WO2010004204A3 (fr) 2010-04-29
CO6440535A2 (es) 2012-05-15
US20110150903A1 (en) 2011-06-23
WO2010004204A2 (fr) 2010-01-14
NZ602905A (en) 2014-05-30
ZA201100209B (en) 2012-04-25
CY1116847T1 (el) 2017-03-15
DK2315781T3 (en) 2015-08-10
AR072699A1 (es) 2010-09-15
EA201170155A1 (ru) 2011-08-30
AU2009267834A1 (en) 2010-01-14
BRPI0915660A2 (pt) 2019-08-27
EP2315781A2 (fr) 2011-05-04
HRP20150836T1 (hr) 2015-09-11
EA201401107A1 (ru) 2015-05-29
JP2015057398A (ja) 2015-03-26
ES2544761T3 (es) 2015-09-03
HK1159133A1 (en) 2012-07-27
EA021580B1 (ru) 2015-07-30
HN2011000074A (es) 2013-01-28
AU2009267834B2 (en) 2014-10-23
MX2011000328A (es) 2011-04-05
CA2730300A1 (fr) 2010-01-14
CR11868A (es) 2011-02-16
CN102149730A (zh) 2011-08-10
PT2315781E (pt) 2015-09-21
UA107782C2 (ru) 2015-02-25
CN102149730B (zh) 2014-03-26
IL210516A0 (en) 2011-03-31
SG10201403751XA (en) 2014-09-26
PL2315781T3 (pl) 2015-10-30
ECSP11010748A (es) 2011-02-28
TW201006492A (en) 2010-02-16
MA32547B1 (fr) 2011-08-01
UY31970A (es) 2010-02-26
EP2315781B1 (fr) 2015-05-06
JP2011527322A (ja) 2011-10-27
JP5726731B2 (ja) 2015-06-03
NI201100012A (es) 2011-07-20
DOP2011000005A (es) 2011-02-15
PE20110313A1 (es) 2011-06-21
KR20110028536A (ko) 2011-03-18
NZ590860A (en) 2012-12-21
SI2315781T1 (sl) 2015-09-30
HUE027221T2 (en) 2016-10-28
CN103784954A (zh) 2014-05-14
FR2933702A1 (fr) 2010-01-15

Similar Documents

Publication Publication Date Title
CL2011000047A1 (es) Anticuerpo antagonista que se une específicamente al receptor 4 del factor de crecimiento fibroblástico (fgf-r4); uso de dicho anticuerpo porque sirve para inhibir la angiogénesis patológica y tratar cáncer hepático y pancreático; composición que lo comprende; linea celular; polinucleótido y vector que comprenden dicho anticuerpo.
ES2657226T3 (es) Anticuerpo monoclonal anti-VEGF y composición farmacéutica que comprende dicho anticuerpo
CL2011001214A1 (es) Dimero de proteina similar a anticuerpo que comprende un decimo dominio de fibronectina de tipo iii (10fn3) que se une a igf-ir; unido covalentemente o no covalentemente con un 10fn3 que se une a egfr; composicion farmacéutica que lo comprende; uso de dicha composicion para tratar transtornos hiperproliferativo.
AR075896A1 (es) Anticuerpos anti-her (factor de crecimiento epidermico)
CL2007001624A1 (es) Uso de un anticuerpo que se une a dll4 para el tratamiento de tumor, cancer o trastorno de proliferacion celular.
CR10147A (es) "ligandos que tienen especificidad de enlace para vegf y/o egfr y métodos de uso de los mismos"
CL2007003794A1 (es) Anticuerpo anti-receptor del factor de crecimiento insulinico i (igf-ir); polinucleotido que lo codifica; metodo de produccion; composicion que lo comprende; y su uso para tratar cancer.
EA201100306A1 (ru) Производные циклогексиламида и их применение в качестве антагонистов рецептора crf-1
EA200970210A1 (ru) Prlr-специфическое антитело и его применения
GT200500298A (es) Formulaciones de anticuerpos
EA201270308A1 (ru) Конъюгаты димеров пирроло [1,4]бензодиазепина в качестве противоракового средства
ATE541571T1 (de) Diarylhydantoin-verbindung
EA200900403A1 (ru) Соединения, которые модулируют рецептор св2
PE20120902A1 (es) Anticuerpos anti-egfl7 humanizados
SV2011003834A (es) Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c5
CL2011002942A1 (es) Compuestos derivados de 2,4-diamino-pirimidina, agonistas de receptor tipo toll-7 (tlr7); composicion farmaceutica; y su uso para el tratamiento del cancer.
AR060241A1 (es) Composiciones y metodos de uso para anticuerpos de c-met
CL2012000623A1 (es) Compuestos derivados de 4-[4,4-dimetil-5oxo-3-(piridin-ilmetil)-2-tioxoimidazolidin-1-il]-2-(trifluorometil)benzonitrilo, con propiedades antiandrogenicas; metodo de preparacion; composcion farmaceutica; y su uso para el tratamiento y/o profilaxis de cancer de prostata.
CL2011000230A1 (es) Anticuerpo monoclonal humano aislado que se une al inhibidor de la via del factor tisular (tfpi); composicion farmaceutica que lo comprende; uso para tratar deficiencias adquiridas o geneticas de la coagulacion, o para acortar el tiempo de sangrado.
ATE496051T1 (de) Pyrazolotetrahydropyridinderivate als orexinrezeptorantagonisten
EA201200019A1 (ru) Соединения, которые селективно модулируют рецептор св2
CL2008002782A1 (es) Anticuerpo anti-bv8 neutralizante; composicion que lo comprende; y su uso para tratar tumores en humanos previamente tratados con un antagonista del factor de crecimiento endotelial vascular.
EA201100523A1 (ru) Соединения сульфонила, которые селективно модулируют рецептор св2
PE20091713A1 (es) Inhibicion del receptor para la proteina estimulante del macrofago (ron), composiciones y metodos
ATE554769T1 (de) Neuromuskuläre blocker mit mittlerer dauer und antagonisten advon